Inside Solid Tumor Therapies With BlueSphere Bio's CEO Dr. David Apelian
Source: Cell & Gene
BlueSphere Bio's CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why.
This website uses cookies to ensure you get the best experience on our website. Learn more